Novartis, Ionis' experimental heart drug misses key goal in closely watched trial - Reuters
Novartis, Ionis' experimental heart drug misses key goal in closely watched trial Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNOUxoV0pmRFpRcnNRQm1TU1N0YXF1RDE2RXp1RWE2NXF6UGJqU1hRYzFLMlhPRi1FZVotdTJjU0xsMVpoMnU2ZXM5UVlQbmFfYy16NGswZzJJUjNjUEJ3MVlfaUVFUU03OVpCblBmVUpEeUhFQkdWUnhjTWI5alBpa0c0cXRVQjE1QjFTQWZDTzh4cW11TEhURC12N0M5VU5pRWNyTUZYY3pxV3lqOG1jY2d5UEYycTlKLXJ6dWRodUttQWZVY194elJkNGJMNGpjem1v?oc=5" target="_blank">Novartis, Ionis' experimental heart drug misses key goal in closely watched trial</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMHalozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PM